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The Pah-R261Q mouse reveals oxidative stress
associated with amyloid-like hepatic aggregation
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Phenylketonuria (PKU) is caused by autosomal recessive variants in phenylalanine hydro-
xylase (PAH), leading to systemic accumulation of L-phenylalanine (L-Phe) that may reach
neurotoxic levels. A homozygous Pah-R261Q mouse, with a highly prevalent misfolding var-
iant in humans, reveals the expected hepatic PAH activity decrease, systemic L-Phe increase,
L-tyrosine and L-tryptophan decrease, and tetrahydrobiopterin-responsive hyperphenylala-
ninemia. Pah-R261Q mice also present unexpected traits, including altered lipid metabolism,
reduction of liver tetrahydrobiopterin content, and a metabolic profile indicative of oxidative
stress. Pah-R261Q hepatic tissue exhibits large ubiquitin-positive, amyloid-like oligomeric
aggregates of mutant PAH that colocalize with selective autophagy markers. Together, these
findings reveal that PKU, customarily considered a loss-of-function disorder, can also have
toxic gain-of-function contribution from protein misfolding and aggregation. The proteostasis
defect and concomitant oxidative stress may explain the prevalence of comorbid conditions
in adult PKU patients, placing this mouse model in an advantageous position for the discovery
of mutation-specific biomarkers and therapies.
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Phenylketonuria (PKU; MIM261600) is an autosomalrecessive inborn error of metabolism characterized by theinability to break down the amino acid L-phenylalanine (L-
Phe). PKU is primarily caused by mutations in the human PAH
gene (NM_000277.2) encoding phenylalanine hydroxylase (PAH;
EC 1.14.16.1). PAH is a tetrameric, non-heme iron aromatic
amino acid hydroxylase that catalyzes the hydroxylation of L-Phe
to L-tyrosine (L-Tyr) using molecular oxygen as additional sub-
strate and the cofactor (6R)-5,6,7,8-tetrahydrobiopterin (BH4)1,2.
This is the rate-limiting step in the catabolic degradation of L-
Phe, which occurs predominantly in the cytoplasm of hepatic
cells. A consequence of deficient PAH catalysis is the accumula-
tion of L-Phe in the blood and ultimately in the brain of untreated
patients, causing growth retardation, intellectual disability, and
behavioral and neuropsychiatric disorders3. PKU has a prevalence
of approximately 1:10,000 livebirths worldwide and can be clas-
sified, based on the off-diet blood L-Phe concentrations, as mild
hyperphenylalaninemia (HPA) (120–600 µmol/L), mild PKU
(600–1200 µmol/L), and classic PKU (>1200 µmol/L)3. The low-
Phe diet is the cornerstone of PKU/HPA management and pre-
vents the most severe consequences of the disease. However,
controlled studies have shown that early treated PKU patients
present several psychiatric disturbances as adults, notably
depression and anxiety-related disorders4. Moreover, recent
investigations have revealed an elevated risk of comorbidities with
unexplained etiology in both early- and late-treated adult PKU
patients, with a high prevalence of cardiovascular and renal dis-
eases and overweight5,6. In the last years, many new treatments
for PKU have been approved or are in clinical development7. A
fraction of patients typically with mild and moderate PAH
mutations are responsive to synthetic formulations of BH4
(Sapropterin, Kuvan®), which is often used in combination with a
less restrictive diet8. Notwithstanding the considerable amount of
accumulated knowledge on PKU, there is a need for a more
profound mechanistic and pathophysiological understanding of
the disease, as well as novel therapies. These required studies
would greatly benefit from the availability of useful model
organisms.
Mouse (Mus musculus) models are a powerful research tool
owing to the small size, high reproductive rate, and relative ease
of genetic manipulation, compared to other mammals, and are
therefore most commonly selected to study human disease9.
There are evident differences between mice and humans, pri-
marily related to evolutionary divergences, for instance in size,
metabolic rate, life expectancy, and immune system, but overall,
the genetic and physiological similarities are high9. The first
generation of mouse models of PKU were created by phenotype-
driven N-ethyl-N-nitrosourea (Enu) germline mutagenesis. In
this manner, three HPA/PKU mouse models have previously
been established; namely, (i) Enu1 (enu1 allele), with the p.
V106A-PAH mutation, located in the PAH regulatory domain10;
(ii) Enu2 (enu2 allele), with the p.F263S-PAH mutation, located
in the catalytic domain10; and (iii) Enu3 (enu3 allele), with a splice
site mutation generating frameshifted amino acids and premature
termination codon11. Enu2 and Enu3 mice exhibit high blood L-
Phe concentrations (>1200 µmol/L) and appear as suitable
models for severe, classic PKU, with a total absence of PAH
activity albeit normal protein stability (Enu2), or total absence of
expressed PAH protein and activity (Enu3)11. In contrast, Enu1
mice present reduced PAH stability and thus decreased steady-
state levels of PAH protein and enzymatic activity (approximately
5% of normal controls), leading to mild HPA12. The available
mouse models have undoubtedly contributed to a better under-
standing of PKU at a biochemical and behavioral level and have
allowed testing of novel therapies such as enzyme substitution13
or genome base editing14. An increasing body of evidence
indicates that PKU is a prototypic genetic conformational dis-
order wherein the principal pathogenic determinant is the degree
of PAH protein instability caused by the specific mutations15. The
available strains do not adequately represent this primary
pathogenic mechanism (Enu2 and Enu3) or include murine
mutations that are non-existent or low recurrent in the human
PAH gene (Enu1), prompting us to generate a PKU mouse model
with a common PAH mutant associated with protein misfolding.
There are over 1100 registered human PAH variants (http://
www.biopku.org/), among which the nucleotide aberration c.782
G > A in Pah exon 7 coding for p.Arg261Gln (p.R261Q) mutation
seems to be an optimal candidate to generate a knock-in mouse
model. The R261Q mutation is one of the most abundant among
PKU patients, with an average allele frequency of approx. 6% (9-
14% in Mediterranean countries and the Middle East) and ~2% of
patients homozygous for this mutation (up to 12% in Medi-
terranean countries and the Middle East)15,16 (http://www.
biopku.org/). The associated phenotype when in homozygosity,
exhibits an unusual and unexplained variability from mild PKU
to classic PKU, with approximately 78% of the patients being
responsive to BH415–17 (http://www.biopku.org/). The R261Q
mutation has been predicted15 and indeed proven to result in
unstable and misfolded PAH18,19.
Hence, in the reported custom-made mouse model, the mutation
c.782G >A was introduced in the Pah gene by CRISPR/Cas9 tech-
nology based on the use of programmable nucleases as a tool for
targeted gene-editing, which is an efficacious and precise genome
engineering method20. In this work, we present the generation and
metabolic, biochemical and biological characterization of this Pah-
R261Q knock-in mouse line. The results obtained highlight (i) the
robustness of this mouse model as a general archetype for mild HPA
associated with PAH instability and misfolding, and (ii) the obser-
vation of large amyloid-like aggregates of mutant (p.R261Q-PAH)
in vivo, which appears associated to the observed proteostasis dys-
regulation, oxidative stress and additional comorbidities. Overall, the
Pah-R261Q mouse model paves the way for new exploratory ave-
nues of research and treatment.
Results
Generation, genotyping, and breeding of Pah-R261Q mice.
There is a high PAH sequence homology (92.5% identity) between
mouse and human PAHs, with Arg261 being in an evolutionarily
conserved region (Supplementary Fig. 1a). Structurally, the residue
Arg261 establishes several intra- and inter-subunit H-bonding and
electrostatic contacts in the dimers that are crucial to maintaining
the stability of the protein as well as proper oligomeric
configuration21,22 (detailed in Supplementary Fig. 1b, c). The
mutation p.R261Q is thus expected to trigger disruption of this
interaction network and, as seen in expression analyses in different
systems, elicit an unstable protein18,19,23 without substantially
affecting the catalytic efficiency of the folded tetramer19.
The custom-made mouse model with the p.R261Q-PAH
mutation was generated by CRISPR/Cas9 genome editing
technology, as schematically represented in Supplementary
Fig. 2a, and proven to have the correct genotype (Supplementary
Fig. 2b, c). The designed primers for genotyping amplified a 537
bp polymerase chain reaction (PCR) product, which, after
restriction fragment analysis with endonuclease BsmI, made it
possible to discriminate electrophoretically between PahWT/WT (2
fragments: 294 and 243 bp), homozygous PahR261Q/R261Q (3
fragments: 243, 171, and 123 bp), and heterozygous PahR261Q/WT
(4 fragments: 294, 243, 171, and 123 bp) mice (Supplementary
Fig. 2c). There is evidence that BLAST hits with three or more
total nucleotide mismatches have a low probability of off-target
effects, specifically if two of these mismatches are situated in the
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seed region24. In any case, we evaluated all 16 candidate loci
susceptible to being secondarily affected by the guide RNA
sequence (Supplementary Table 1). These genes were subjected to
heteroduplex analysis, all showing wild-type sequence, with no
detection of off-target interactions.
A retrospective examination of the maternal genotype effect in
the breeding revealed no abnormalities between homozygous
PahR261Q/R261Q mice (referred to as Pah-R261Q) and PahWT/WT
(WT) mice with respect to litters per mated female (3.7 ± 0.6 vs.
4.0) and progeny per litter (7.1 ± 0.4 vs. 7.0)25. Furthermore, the
compilation of historical data confirmed the expected offspring
genotypic distribution as predicted by Mendelian laws.
Pah-R261Q mice exhibit mild HPA, higher body weight in the
case of males, and reduced respiratory exchange ratio. Pah-
R261Q mice presented a small but significant increase in basal blood
L-Phe levels, measured in dried blood spots in 3-month old mice
(108.0 ± 36.6 µM, n= 23 mice) compared to both WT (59.9 ± 7.7
µM, n= 9; p < 0.0001) and heterozygous PahR261Q/WT (71.22 ±
21.86 µM; n= 6; p= 0.0201), analyzed by Brown–Forsythe and
Welch ANOVA test followed by Dunnett’s multiple comparisons
tests. Source data are provided as a Source Data file. The blood L-
Phe level in Pah-R261Q corresponds to very mild HPA in human
subjects. In contrast to the Enu2 PKU mouse model, which presents
weight and length reduction, hypopigmentation, behavioral, and
neurological problems26, Pah-R261Q were no different from their
heterozygote and WT counterparts in length, pigmentation, and
behavior. Three-month-old male Pah-R261Q mice, however, were
weightier than their WT counterparts (27.8 ± 0.4 vs. 25.1 ± 0.3 g,
respectively) (Fig. 1a). Pah-R261Q females were as expected lighter
than males and were not different in weight than their WT coun-
terparts (22.1 ± 1.6 vs. 21.1 ± 1.4 g, respectively). Apart from the
higher body weight in mutant males, we did not find gender-
associated variations for any other parameter or metabolite mea-
sured in this work; thus, the mice groups for each experiment
included evenly distributed males and females.
Various physiological murine parameters were controlled for
the 48 h metabolic cage examinations for WT and Pah-R261Q
(12 h acclimatization and 36 h of measured observations). The
amount of food intake was equal (Fig. 1b), and no significant
changes in activity and movement patterns were identified
(Fig. 1c). However, the rates of O2 consumption and CO2
production normalized to body mass (VO2 and VCO2, respec-
tively) were both decreased for Pah-R261Q compared with WT
(Fig. 1d and Supplementary Fig. 3a, b), and the calculated
respiratory exchange ratio (RER=VCO2/VO2) was also slightly
lower for Pah-R261Q than forWT (0.988 ± 0.087 vs. 1.014 ± 0.093;
the average for the total 36 h experimentation) (Fig. 1e, inset).
RER values are approximately 1.0, 0.8, and 0.7 for carbohydrates,
proteins, and fat, respectively, as sole metabolic fuel27. Never-
theless, in heavy activity periods RER increases and reaches values
>128, and RER values reflect metabolic fuel utilization more
accurately during periods of rest or mild exercise29. During the
12 h resting period, RER was closer to 0.8 for Pah-R261Q and 1 for
WT mice (Fig. 1e), indicating a higher utilization of fat and
protein as a fuel source during this period among the mutant
mice30. The decreased RER at rest also contributed to lower
energy expenditure in the same period compared with WT mice,
even for non-weight-normalized values (Fig. 1f), although this
difference did not translate into significantly lower energy
expenditure for the mutant mice per day.
Metabolic characterization of Pah-R261Q mice show lipid
metabolism alterations and oxidative stress. Detailed metabolic
profiling of Pah-R261Q compared with WT mice was performed
by measuring 72 relevant metabolic biomarkers in extracted
blood serum samples from 4-month-old mice. The complete list
of metabolites and the results obtained are presented in Supple-
mentary Table 2. Table 1 summarizes the individual values for the
17 metabolites displaying differences at p < 0.1 level, with either
higher or lower blood serum concentrations for Pah-R261Q
compared to WT. This p value was selected to avoid type II error
due to the limited sample size.
A blood serum L-Phe concentration in the mutant mice
corresponding to very mild HPA (113 ± 22 µM vs. 71.9 ± 10.3 µM
for WT) was obtained in this study, similar to the values obtained
from dried blood spots (see above). As seen in Table 1, the increased
serum L-Phe was accompanied by decreased levels of L-Trp and L-
Tyr, markers of the HPA phenotype, as well as decreased quinolinic
acid and a trend for reduced kynurenine, both downstream
metabolites of L-Trp. Interestingly, serum trimethyllysine, leucine,
and isoleucine, which have been shown to increase in adiposity and
altered lipid metabolism in humans31, were elevated in Pah-R261Q
(Table 1). Moreover, increased β-hydroxybutyrate is also an
established biomarker associated with impaired glucose homeostasis,
diabetes, and defense against oxidative stress32,33. Also, other serum
metabolites observed in lower concentrations in Pah-R261Q have
previously been linked to oxidative stress and immune function,
such as α-ketoglutaric acid, glutamic acid, and quinolinic acid34–37.
These biomarkers are tightly associated metabolically to creatine and
methylmalonic acid, and to the amino acids aspartic acid, alanine,
glutamine, and proline, all with decreased trends (Table 1).
The incorporation of these metabolites to the Krebs cycle—a
central hub of metabolism—through anaplerotic reactions is
increased in situations of oxidative and cellular stress38. Further-
more, the reduction in anaplerotic metabolites and increase in β-
oxidation in Pah-R261Q are in agreement with increased utilization
of proteins and fats as an energy source, as also inferred by the lower
resting-state RER in these mice compared to WT (Fig. 1e). We
acknowledge that the use of a high, explorative p value cutoff
(p < 0.1) may have generated spurious hits among the metabolite
biomarkers. However, we believe that the approach is justified by the
overall coherence of the findings that support lipidic metabolic
alterations and oxidative stress in the Pah-R261Q mice, in addition
to the expected mild HPA.
Pah-R261Q mice show no apparent neurological alteration but
a remarkable decrease of hepatic BH4. The elapsed time for a
mouse to maintain its balance on a rotating rod is a good indi-
cator of possible neurological deficits, as shown for the Enu2
mouse39. As illustrated in Supplementary Fig. 3c, Pah-R261Q had
comparable performance to WT on the rotarod test, supporting
that the PAH mutation has no impact in neuromuscular function
or motor coordination, at least for young mice. We also corro-
borated no alterations in the levels of aromatic amino acids L-
Phe, L-Tyr, and L-Trp (Supplementary Table 3) and monoamine
neurotransmitters (Fig. 2a) in the brain. In addition, as seen in
Fig. 2, we confirmed no significant difference in the total levels of
BH4 in the brain, where BH4 acts as a cofactor of the other
aromatic amino acid hydroxylases tyrosine hydroxylase (TH) and
tryptophan hydroxylase 2 (TPH2) and of neuronal nitric oxide
synthase (NOS)2. However, the concentration of BH4 in the liver,
where it acts as the essential cofactor for the hydroxylating
PAH reaction, showed a startling 50% reduction in Pah-R261Q
(28.0 ± 1.7 pmol BH4/mg protein) compared with WT mice
(56.2 ± 3.2 pmol/mg) (Fig. 2b).
Pah-R261Q mice are sensitive to L-Phe challenge concomitant
with BH4 responsive hyperphenylalaninemia. When we admi-
nistered Pah-R261Q mice an L-Phe challenge—equivalent to the
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L-Phe loading test that is applied to HPA/PKU patients for their
phenotypic classification40—a transient but very prominent ele-
vation of blood L-Phe values was observed. As shown in Sup-
plementary Fig. 4, 40 min after i.p. injection with 200 µg L-Phe/g
body weight, Pah-R261Q mice presented a massive increase in
L-Phe concentrations (990 ± 220 µM), before returning to basal
levels ca. 300 min later. A similar L-Phe challenge caused much
lower increases of L-Phe concentrations in heterozygous and WT
mice (Supplementary Fig. 4). The transient L-Phe-increase in
Pah-R261Q mice allowed us to investigate the response to
Fig. 1 Physiological and metabolic characterization of Pah-R261Q compared withWTmice. a Bodyweight distribution by sex and genotype. The weight of
WT mice (controls) was in agreement with averaged registered data (https://www.jax.org/strain/000664). Data are presented as mean ± SD, with
individual values plotted as circles (females) and triangles (males) (n= 10 WT male, 14 WT female, 31 Pah-R261Q male, 26 Pah-R261Q female mice).
Statistical significance for the weight difference for males in the two groups was calculated by two-tailed unpaired t test; p= 0.0031 (**). b–f Metabolic
cage experiments, performed for 48 h, with 12 h of acclimation followed by 36 h of recordings. n= 3 WT and 5 Pah-R261Q mice in independent
experiments, with one mouse per cage and 121 observations/animal. b Cumulative feed consumption (g). c Mice activity with continuous recording,
expressed as mean ± SD. Inset, total activity for each mouse group presented as mean ± SD, individual values are plotted as circles. d Total Volume of O2
consumed and volume of CO2 produced for each mice type, obtained from the integration of the area under the curve (AUC) from data in Supplementary
Fig. 3. Data are presented as the mean AUC ± SD, with individual values plotted as circles. Statistical significance for the difference between both mice
groups was calculated by two-tailed unpaired t test; p= 0.0011 (**) for O2 and p < 0.0001 (****) for CO2. e Respiratory exchange ratio (RER) along the
recording time. Inset: averaged RER presented as mean ± SD; the circles represent mean for the group at each time point. Statistical significance for
differences between both groups was calculated by two-tailed unpaired t test; p < 0.0001 (****). f Energy expenditure obtained by indirect calorimetry
expressed as mean ± SD. In all panels, the data for WT are depicted in purple and Pah-R261Q in ochre. Source data are provided as a Source Data file.
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Table 1 Blood serum concentrations of the metabolites whose levels were increased/decreased in Pah-R261Q mice in respect to
the control WT group. Concentrations are expressed as arithmetic mean ± SD; n= 19 WT and 19 Pah-R261Q mice.
Metabolite (name) WT (µM) Pah-R261Q (µM) Difference p Value (MW)a
Phenylalanine 71.9 (10.3) 113 (22) 41.1 0.0000004
β-Hydroxybutyrate 150 (99) 282 (133) 132 0.029
Trimethyllysine 0.803 (0.165) 0.976 (0.213) 0.173 0.050
Leucine 143 (23) 164 (42) 21 0.075
Isoleucine 87.5 (12.8) 101 (24) 13.5 0.091
α-Ketoglutaric acid 38.6 (15.2) 26.3 (10.8) −12.3 0.003
Glutamic acid 39.5 (20.7) 29.4 (10.2) −10.1 0.008
Alanine 444 (71) 362 (80) −82 0.010
Tryptophan 103 (24) 82.9 (30.9) −20.1 0.013
Quinolinic acid 0.178 (0.090) 0.130 (0.041) −0.48 0.023
Creatine 154 (40) 127 (30) −27 0.026
Aspartic acid 27.4 (14.4) 22.7 (11.0) −4.7 0.043
Glutamine 687 (76) 622 (112) −65 0.043
Tyrosine 81.3 (25.3) 77.9 (14.0) −3.4 0.050
Methylmalonic acid 0.701 (0.095) 0.585 (0.118) −0.116 0.060
Kynurenine 0.740 (0.234) 0.573 (0.264) −0.167 0.080
Proline 90.2 (25.4) 73.0 (17.2) −17.2 0.085
aTwo-tailed p values for differences between serum concentration in WT and Pah-R261Q mice were obtained from Mann Whitney (MW) U test.
See also Supplementary Table 2.
Fig. 2 Neurotransmitter and BH4 content, and BH4-responsiveness in the Pah-R261Q mouse model. a Monoamine neurotransmitter content in brain
lysates; data are presented as mean ± SD, individual values are plotted as circles (n= 5 WT and 5 Pah-R261Q mice). Abbreviations (from left to right):
levodopa, 3-ortho-methyldopa, dopamine, homovanillic acid, norepinephrine, 3-methyl-4-hydroxyphenylglycol, epinephrine, 5-hydroxytryptophan,
serotonin, and 5-hydroxyindoleacetic acid. b BH4 determination in whole brain and liver lysates, presented as mean ± SD, individual values are plotted as
circles (n= 6 WT and 5 Pah-R261Q). Statistical significance for the difference in brain BH4 content between both groups was calculated by two-tailed
unpaired t test; p < 0.0001 (****). c Blood L-Phe concentration after L-Phe challenge in placebo-control (black) and BH4-treated (pink) Pah-R261Q mice
(n= 5 placebo and 6 treated mice). L-Phe (200 µg L-Phe/g body weight) was administered by i.p. at time 0 and L-Phe concentration was monitored at 0,
35, 90, 150, and 300min. The BH4 treated mice received (by i.p.) 20mg/kg BH4 in 2% ascorbic acid and 10% DMSO, for 4 days, twice a day, previous to
L-Phe administration, and the placebo control received the same solution without BH4. Data are presented as mean ± SD. Inset, area under the curve (AUC)
for the time dependence of L-Phe concentration between 0 and 300min for placebo and BH4-treated groups. Individual values are represented by circles.
Statistical significance for the difference between both groups was calculated by two-tailed unpaired t test; p= 0.0299 (*). In panels a and b the data for
WT are depicted in purple and for Pah-R261Q in ochre. Source data are provided as a Source Data file.
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BH4-treatment. As seen in Fig. 2c, significantly lower blood L-Phe
level was measured after an L-Phe challenge (200 µg/g body
weight) was administered following a BH4 treatment (20 mg/kg
body weight for 4 days, twice a day41), compared with placebo.
BH4 treatment resulted in a 28% decrease in L-Phe content as
calculated from the area under the curve (Fig. 2c, inset). Patients
with the R261Q mutation in homozygosity present variable HPA
phenotype but about 74% are positive responders to BH4 treat-
ment (http://www.biopku.org/), and the results with the mutant
mice are consistent with the BH4-responsive phenotype.
Hepatic p.PAH-R261Q protein presents increased ubiquitina-
tion and aggregation. After the investigation of the metabolic
status of Pah-R261Q mice, we also studied the effect of the
mutation on the function and stability of PAH in the mouse liver.
Immunodetection by Western blot of the PAH protein (p.R261-
PAH and WT-PAH, for the mutant and WT proteins, respec-
tively) in liver lysates showed the typical 51-kDa PAH band for
WT mice, and two PAH bands at 51- and 56-kDa for the het-
erozygous PahR261Q/WT and homozygous PahR261Q/R261Q (Pah-
R261Q) mutant mice (Fig. 3a). The 56-kDa PAH band, present in
both mice with the mutant allele, was recognized by the anti-
ubiquitin antibody (Fig. 3b). This band has been identified as
mono-ubiquitinated PAH in previous studies with Enu1 and
Enu1/2 HPA mouse models42,43. The 51-kDa non-ubiquitinated
PAH band was strongly reduced in Pah-R261Q, as best observed
in the immunoquantified PAH levels normalized to WT control
mice (Fig. 3c). We also measured PAH activity in the liver lysates,
and for each genotype, the relative specific activity correlated well
with the relative levels of non-ubiquitinated PAH protein in liver
lysates (Fig. 3c). Nevertheless, the results with Pah-R261Q (11.6 ±
1.5% non-ubiquitinated protein vs. 16.9 ± 3.3% specific activity,
both relative to WT) support low level of PAH activity for the
ubiquitinated enzyme.
The reduction of total p.R261Q-PAH protein levels and
increased ubiquitination observed by Western blot in Pah-
R261Q compared to WT mice, indicative of instability and
misfolding of this PAH variant (Fig. 3a, b), was followed-up by
immunofluorescence staining of hepatic tissue which confirmed a
substantial reduction in PAH protein in Pah-R261Q (Fig. 4). The
specificity of the PAH antibody was further proven by an antigen
pre-adsorption test showing almost complete loss of PAH
immunoreactivity in hepatic tissue of WT mice after incubation
with PAH antibody preabsorbed with purified recombinant PAH
(Supplementary Fig. 5). Moreover, the immunofluorescence
images of Pah-R261Q revealed scattered PAH-immunoreactivity
in discrete bright points, consistent with aggregation, as well as an
increase in ubiquitination signal that presented substantial
colocalization with mutant PAH (Fig. 4). To investigate the
mutation dependent PAH misfolding and aggregation, we also
performed immunofluorescence of hepatic tissue of the Enu1
mouse model of mild HPA, which expresses the unstable p.
V106A-PAH variant, also associated with PAH instability,
leading to a considerable decrease of functional PAH in the liver
(5% of WT)42,44,45. Enu1 liver also presented largely decreased
Fig. 3 PAH content in liver lysates of homozygous and heterozygous Pah-R261Q mice. a Western blots for immunodetection of PAH (α-PAH) (a) and
ubiquitinated protein (α-Ub) (b) showing the decrease in non-ubiquitinated PAH (non-Ub-PAH; ~51 kDa band) and increase of mono-ubiquitinated PAH
(mono-Ub-PAH; ~56 kDa) from genotype PahWT/WT to PahR261Q/WT to PahR261Q/R261Q. The blots are representative from n= 3 replicates for each
mice group. GAPDH was used as loading control. c Overview of relative PAH specific activity normalized to activity in PahWT/WT liver lysates (23.2 ±
2.4 nmol L-Tyr/min/mg protein) (n= 4 mice for each genotype) and non-Ub-PAH protein (51 kDa) levels from densitometric analysis normalized to both
PahWT/WT liver lysates as well as to GAPDH loading control (n= 3 mice for each genotype). Data are presented as mean ± SD for PahWT/WT (purple),
PahR261Q/WT (green), and PahR261Q/R261Q (ochre), individual values are represented as circles. Differences between genotypes were analyzed by one-way
ANOVA followed by Tukey test; differences in PAH activity, p= 0.0005 (***) for PahWT/WT vs. PahR261Q/WT, p < 0.0001 (****) for both PahWT/WT vs.
PahR261Q/R261Q and PahR261Q/WT vs. PahR261Q/R261Q; differences in PAH level, p= 0.0080 (**) for PahWT/WT vs. PahR261Q/R261Q. Source data are provided as
a Source Data file.
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and particulate PAH-immunoreactivity and increased ubiquitina-
tion. There were, however, differences in the aggregation pattern
of mutant PAH between both HPA-mouse models (Fig. 4) as
well as in the size of the PAH aggregates, larger in Pah-R261Q
than in Enu1.
We further studied the distribution of PAH aggregates between
the nucleus and the cytoplasm in hepatic cells. The use of the
nuclear pore marker Nup98 and 3D-rendering of the stacks of
confocal images revealed that the smaller aggregates of mutant
PAH in Enu1 appeared more ubiquitously distributed in
hepatocytes, where they are also present in the nucleus (Fig. 5a).
On the other hand, the PAH aggregates in Pah-R261Q did not
show nuclear localization and appear distributed at the cytoplas-
mic side of the nuclear membrane (Fig. 5a). As fluorescence
detection may alter the shape and size of macromolecules and
complexes, we also performed immunohistochemistry (IHC) with
optical detection by DAB staining in order to assess the size of the
mutant PAH aggregates in hepatic tissue (Fig. 5b, c). The averaged
area of DAB-stained particles was 0.18 ± 0.06 and 0.11 ± 0.03 (SD)
µm2 for Pah-R261Q and Enu1, respectively (Fig. 5c).
Amyloid-like aggregation of p.PAH-R261Q. The different size
and nucleocytoplasmic distribution of the aggregates of p.R261Q
and p.V106A PAH variants in Pah-R261Q and Enu1 livers,
respectively, suggests different misfolding and aggregation
mechanisms for these two mutants. As larger aggregates,
especially those with amyloid aggregation, can be cytotoxic46, we
investigated if the mutant protein p.R261Q-PAH could aggregate
through cross-β-sheet prone motives around the mutation site.
Positively, in silico evaluation with the program TANGO47 pre-
dicted a high (>50%) propensity to form intermolecular cross-β
(amyloid-like) aggregates in region 254–263 in the mutant
(FLGGLAFQVF), while the same region in the WT sequence
(FLGGLAFRVF) was not predicted to be prone to amyloid-like
aggregation (Supplementary Fig. 1), for both the human and
mouse PAH sequences. We tested the propensity of all PAH
missense variants registered at BIOPKU (http://www.biopku.org),
and also included p.V106A-PAH (Enu1), which is very rare in
human48. The calculations supported a high susceptibility
to undergo this type of aggregation for a few variants, i.e., p.E78V,
p.N167Y, p.P211L, p.R261G, and p.E390G, all rare, but not for
p.V106A (Enu1).
To confirm the formation of amyloid-like aggregates by the
mutant p.R261Q-PAH we used the Amytracker™ 680 fluorescence
assay with purified recombinant mutant protein. An accelerated
formation of amyloid-like aggregates was observed for p.R261Q-
PAH compared to WT-PAH (Supplementary Fig. 6a). After 5 h
incubation, parallel samples of p.R261Q-PAH without Amy-
tracker were visualized by transmission electron microscopy
(TEM). Imaging revealed larger amorphous aggregates of a
diameter up to >100 nm, together with small aggregates of about
20 nm diameter, whereas fibrillary structures were not observed
(Supplementary Fig. 6b).
Fig. 4 Distribution of PAH in hepatic tissue ofWT and mouse models Pah-R261Q and Enu1. Immunofluorescence of PAH and ubiquitin (Ub) detection in
hepatic tissue ofWT, Pah-R261Q, and Enu1mice, revealing the distribution pattern of PAH (green) and Ub (red). PAH was strongly reduced in both Enu1 and
Pah-R261Q when compared to WT, whereas Ub was highly expressed in both mutant mice. The micrographs are representative for n= 3 biological
replicates in each mice group. The fluorescence intensity (mean ± SD) calculated in 14 stacks of confocal images, relative to WT (=1), was 0.264 ± 0.105
(Pah-R261Q) and 0.154 ± 0.029 (Enu1) for PAH, and 1.315 ± 0.035 (Pah-R261Q) and 1.405 ± 0.103 (Enu1) for Ub. Colocalization of PAH and ubiquitin
(yellow) was observed in both mutant mice, as highlighted in the inset. DAPI was used for nuclear staining (blue). Source data are provided as a Source
Data file.
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PAH aggregates in Pah-R261Q mice colocalize with autophagy
markers and are associated with oxidative stress. Larger aggre-
gates are commonly processed by autophagy rather than by the
ubiquitin-dependent proteasome system (UPS)49. We thus per-
formed immunofluorescence microscopy of liver samples of WT,
Pah-R261Q, and Enu1 mice with autophagy markers Ser403-
phosphorylated p62 protein (p62/SQSTM1 (sequestosome-1)), a
selective receptor and marker for autophagic clearance50,51. The
level of phosphorylated p62 (P-p62) was indeed much higher in
Pah-R261Q than in Enu1 mice, which presented similar immu-
nodetected levels as in WT mice (Fig. 6a). Immunofluorescence
staining with the standard marker for autophagosomes LC3 was
also increased in Pah-R261Q, but not in Enu1, compared with WT
(Fig. 6b). Both autophagy markers P-p62 and LC3 presented
colocalization with mutant PAH in Pah-R261Q mice (Fig. 6a, b).
These results suggest that the larger PAH aggregates in Pah-
R261Q, but not the smaller aggregates in Enu1, engage the
autophagic system. Moreover, we also performed TEM imaging of
hepatic tissue, which showed hepatocytes with normal cell and
organelle morphology in Pah-R261Q and no abnormality in nuclei
or the nuclear membrane (Supplementary Fig. 7a). We noticed
an increased number of lysosomes and of autophagic structures,
Fig. 5 Nuclear distribution of mutant PAH protein in Pah-R261Q and Enu1 mice liver. a Immunofluorescence of PAH (green) and the nuclear pore marker
Nup98 (red) in hepatic tissue of Enu1 and Pah-R261Q mice (left panels), and 3D-rendering of stacks of confocal images using the surface tool in Imaris
software at two different magnifications (middle and right panels). The images reveal the subcellular distribution of PAH in the nucleus and cytoplasm of
Enu1 mice, whereas in Pah-R261Q mice PAH is distributed in the cytoplasm. Hoechst was used for nuclear staining (blue). b Immunohistochemically DAB-
stained hepatocytes from WT, Pah-R261Q, and Enu1 mice at low (left panels) and high (right panels) magnification. Arrows indicate PAH immunoreactive
hepatocytes in Pah-R261Q and Enu1 mice. a, b The micrographs are representative of n= 3 biological replicates in each mice group. c Two representative
PAH immunoreactive hepatocytes at higher magnification in Pah-R261Q (left) and Enu1 (right) mice are shown, where arrowheads point to PAH-positive
particle-like structures. Measurement of PAH particle size was performed in 30 µm-thick liver sections (n= 10) for each mice. At least 400 single PAH-
positive particles in randomly selected regions of liver sections from each mice group were analyzed, and the size distribution of PAH-positive particles in
Pah-R261Q and Enu1 hepatocytes is shown (lowest panel). Data are presented as mean ± SD and each dot represents a PAH-positive particle. The difference
in size is statistically significant, as calculated by the two-tailed unpaired t test; P value < 0.0001 (****). Source data are provided as a Source Data file.
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i.e., double-membrane autophagosomes and autolysosomes (Sup-
plementary Fig. 7b) and exhaustive counting of these structures
confirmed that they were increased in Pah-R261Q compared to
WT mice whereas no difference in the number of peroxisomes and
lipid drops was found (Supplementary Fig. 7c).
The nuclear quality control system customarily collaborates on
the degradation of misfolded cytoplasmic proteins and small
aggregates52. However, larger aggregates may hinder nuclear
uptake46, leading to toxic accumulation of the aggregates in the
cytoplasm, saturation of the autophagy system, and increased
oxidative stress49,53. For some aggregation disorders associated
with the formation of amyloid fibrils by Tau, such as
polyglutamine diseases, AD and Tau-dementia, invaginations or
indentations of the nuclear membrane, filled by fibrillary rods, as
well as nuclear pore pathology are observed54,55. These alterations
are also observed in ALS/FTD caused by aggregation of TDP-43
in non-fibrillary oligomeric amyloid-like aggregates56 and seem
related with the interference of the proteins with the nucleocy-
toplasmic system, e.g., microtubules in the case of Tau54 or the
nuclear transport machinery in the case of TDP-4356, resulting in
the invaginations. The lack of nuclear invaginations in Pah-
R261Q is in accordance with the non-fibrillary nature of the PAH
Fig. 6 Colocalization of mutant PAH in Pah-R261Q mice with autophagic markers. Immunofluorescence micrographs showing the codistribution of PAH
(green) with autophagy markers p62 phosphorylated at Ser403 (P-p62, red) in (a) or LC3 (red) in (b) in hepatic tissue from WT, Pah-R261Q and Enu1 mice. Both
markers were increased in Pah-R261Q when compared to both WT and Enu1. The fluorescence intensity (mean ± SD) calculated in 14 stacks of confocal images,
relative to WT (=1), was 1.326 ± 0.121 (Pah-R261Q) and 0.778 ±0.158 (Enu1) for P-p62 (a), and 2.277 ± 0.174 (Pah-R261Q) and 1.535 ± 0.175 (Enu1) for LC3
(b). Pah-R261Q but notWT or Enu1 showed clear colocalization (yellow) of PAH with both P-p62 (a) and LC3 (b), as highlighted in the insets. Hoechst was used for
nuclear staining (blue). All micrographs are representative for n= 3 biological replicates in each mice group. Source data are provided as a Source Data file.
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aggregates and with PAH being a cytoplasmic enzyme with no
known functional association with the nucleocytoplasmic system.
Despite a lack of significant disturbances in nuclear morphol-
ogy in Pah-R261Q, it appears that the aggregates of p.R261Q-
PAH do not enter the nucleus (Fig. 5a), which can be associated
with overload of the cytoplasmic quality control system and
oxidative stress. We measured the total equivalent antioxidant
capacity (TEAC) in liver lysates of both HPA models (Enu1 and
Pah-R261Q) and WT mice by the Trolox assay. Pah-R261Q but
not Enu1 presented elevated TEAC values compared with WT
(Supplementary Fig. 8), indicating a specific upregulation of the
antioxidant response in Pah-R261Q mice in agreement with the
metabolic changes associated with oxidative stress (see above and
Table 1).
Gene (mRNA) expression assays. Finally, ten genes related to the
PAH system, protein quality control, and oxidative stress path-
ways were selected and subjected to analysis by quantitative
TaqMan mRNA expression in liver extracts (RT-qPCR; results
overview in Table 2). In absolute terms, Pah and Hsc70 showed
the highest levels of gene expression. Comparatively, for Pah-
R261Q vs. WT mice, we found the following: (i) Pah expression
was not altered; (ii) expression of the GCH1-feedback regulatory
(Gchfr) gene was upregulated; (iii) the PAH specific Hsp40 co-
chaperone Dnajc12 exhibited increased expression levels while
two heat shock family members, namely the transcription factor
Hsf1 and the molecular chaperone Hsp70 were downregulated,
and the expression of the constitutive Hsc70 was unmodified; (iv)
no significant changes in expression levels were identified for
targets associated with protein degradation, Stub1 (coding for
the co-chaperone CHIP, with ubiquitin ligase activity) and the
autophagy marker Sqstm1 (coding for p62/SQSTM1), and for the
oxidative stress-responsive transcription factor Ap-1. The impli-
cation of these results together with the other findings in this
work are discussed below.
Discussion
Mouse models of genetic diseases do not always entirely recapi-
tulate the main phenotypic characteristics found in patients9. The
Pah-R261Q knock-in mouse that carries a frequent mutation in
HPA/PKU patients exhibits reduced total hepatic PAH activity
and presents phenotypic traits characteristic of homozygous
patients with the R261Q:R261Q genotype, such as increased L-Phe
and decreased L-Trp and L-Tyr in blood compared to WT, sen-
sitivity to L-Phe challenge, and responsiveness to BH4 supple-
mentation (http://www.biopku.org)8,16. Moreover, there is similar
PAH residual activity (~15% ofWT) in both Pah-R261Qmice and
homozygous humans16, however, we encountered a remarkable
difference between absolute blood L-Phe-levels in mice and
patients. While patients present metabolic phenotypes from mild
PKU to classic PKU (off-diet blood L-Phe values > 600 µmol/L)
(247 records in http://www.biopku.org; see also refs. 16,17), our
mouse model exhibited very mild HPA (~110 µmol L-Phe/L).
Thus, for the same PAH genotype with similar remaining activity,
the blood L-Phe concentration (metabolic phenotype) is higher in
humans, which might be explained by a lower steady-state level of
hepatic PAH in humans compared with mice. There is a high
similarity in sequence, structure, specific activity and regulatory
properties of human and mouse PAH, and thus different PAH
amounts between rodents and humans have been associated with
differences in the rate of transcription, translation, and/or protein
homeostasis57. Nevertheless, based on the similar propensity to
aggregate through a cross-β-sheet formation for human and
mouse PAH around the mutation area (Supplementary Fig. 1), it
is very probable that similar amyloid-like soluble aggregates are
formed in the liver of patients with the Arg261→Gln mutation.
The Pah-R261Q mouse appears to offer considerable potential
for mechanistic and therapeutic investigations as it presents with
a tunable blood L-Phe concentration. By applying an L-Phe
challenge, we could transiently attain L-Phe concentrations
characteristic of PKU, and by adjusting the L-Phe concentration
and length of supplementation, it might be possible to modulate
the metabolic phenotype and fully develop the capacity of this
mouse model as a prototype to study a range of mild to severe
forms of HPA. Furthermore, upon L-Phe challenge, the resulting
transient HPA in Pah-R261Q is responsive to treatment with BH4
(Kuvan®). Consequently, this mouse model can contribute to
evaluate protocols and understand the multifactorial mechanisms
Table 2 Relative mRNA quantification for selected genes in liver of WT and Pah-R261Q mice.
Gene (name) Pah genotype Expression level (relative to WT mice, defined as 1) Fold changea p Valueb
Pah WT 1.0000 (0.7878 ± 1.2693) 1.15 0.2273
R261Q 1.1524 (1.0967 ± 1.2110)
Gch1 WT 0.2512 (0.2146 ± 0.2939) 1.08 0.5440
R261Q 0.2714 (0.2115 ± 0.3483)
Gchfr WT 0.0163 (0.0131 ± 0.0203) 1.70 0.0024
R261Q 0.0277 (0.0228 ± 0.0336)
Dnajc12 WT 0.0040 (0.0030 ± 0.0053) 1.78 0.0048
R261Q 0.0071 (0.0057 ± 0.0088)
Hsp70 WT 0.0010 (0.0007 ± 0.0015) 0.31 0.0012
R261Q 0.0003 (0.0002 ± 0.0005)
Hsc70 WT 0.9704 (0.7478 ± 1.2592) 1.34 0.0855
R261Q 1.2983 (1.0279 ± 1.6399)
Hsf1 WT 0.0280 (0.0251 ± 0.0313) 0.65 0.0054
R261Q 0.0183 (0.0140 ± 0.0238)
Stub1 WT 0.0156 (0.0126 ± 0.0193) 1.22 0.0808
R261Q 0.0191 (0.0175 ± 0.0208)
Sqstm1 WT 0.2483 (0.2203 ± 0.2799) 1.04 0.6389
R261Q 0.2571 (0.2287 ± 0.2892)
Ap-1 WT 0.0163 (0.0140 ± 0.0189) 1.0 0.9815
R261Q 0.0163 (0.0149 ± 0.0179)
aFold change in Pah-R261Q mice relative to WT mice.
bTwo-tailed p values for differences between both mice groups, obtained from the Mann Whitney U test.
Genes upregulated or downregulated in Pah-R261Q (n= 5 mice) compared to WT (n= 6 mice) (p < 0.05) are highlighted in bold text.
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for BH4 responsiveness in mice, including the increase of
total PAH enzyme activity by PAH variant stabilization through
protection against oxidative damage and proteolytic degradation,
thus prolonging the half-life of PAH as seen in vitro19.
The large variability and spectrum of metabolic phenotypes
presented by homozygous PAH-R261Q patients15–17 are thus far
not observed in the mouse model. Pah-R261Q mice, in fact,
present low variation in the basal concentration of blood L-Phe
and other parameters measured in this work. The proteostasis
network that maintains the synthesis, folding, localization, and
degradation of proteins, and counteracts the effect of aggregates,
involves a large number of protein components that are regulated
at the cellular, tissue, and organismal level53. This complex pro-
teostasis network provides additional polymorphic modifier var-
iants that contribute to the broader phenotypic spectrum in
patients with unstable PAH variants, but not necessarily in the
mouse model where a uniform genetic background has been
achieved by careful backcrossing.
In PKU, the neurological defects include monoamine neuro-
transmitter deficiencies, which are fully manifested in the classical
PKU (Enu2) mouse that is almost devoid of PAH activity26. The
Enu1/2 mouse, which presents 2.5% of regular PAH activity and
blood L-Phe levels just slightly higher (~150 µmol/L) than in Pah-
R261Q, also shows a decrease in brain serotonin and 5HIAA58.
However, the remaining 16% PAH activity in Pah-R261Q mice
appears high enough to result in apparently normal L-Phe cata-
bolism and monoamine neurotransmitter synthesis, as well as in
absence of detectable neurological deficiencies. Nevertheless,
despite their mild HPA, Pah-R261Q mice manifested several
biomarkers and indicators of adiposity and altered lipid meta-
bolism, and oxidative stress. These traits have been previously
observed in patients and animal models of PKU where they have
been related to neurotoxic HPA levels and (micro)nutritional
deficiencies of the L-Phe-free diet59,60, factors that are absent in
this case. Further evidence suggests that the increased weight in
Pah-R261Q males is not a direct consequence of elevated L-Phe
levels; the classical PKU model Enu2 is underweight, despite its
tenfold higher blood L-Phe levels than in Pah-R261Q26. The
molecular basis behind the observed mild overweight and oxi-
dative stress in Pah-R261Q mice appears to be related to a toxic
aggregation of mutant PAH and contributes to the identification
of a gain-of-function contribution to the HPA/PKU pathology.
The misfolding defect of the p.R261Q-PAH protein variant is
manifested both in biochemical characterizations as a reduced
conformational stability and accelerated degradation18,19,23 and
in computational predictions by FoldX15. The Arg to Gln residue
change is expected to disrupt the interdimer interactions in p.
R261Q-PAH (Supplementary Fig. 1), and the area around the
mutation would then become available for unspecific intersubunit
interactions. Among the few HPA/PKU-associated PAH variants
with a high predicted propensity for β-cross amyloid-like aggre-
gation by in silico TANGO calculations47, p.R261Q-PAH is the
variant with the highest allele frequency among patients.
The Pah-R261Q mice presented a reduction in steady-state
hepatic PAH levels and PAH-specific activity, as well as increased
ubiquitination of the protein in the liver. The current under-
standing of the loss-of-function of misfolding PAH variants is an
accelerated degradation carried out preferentially by the
ubiquitination-dependent proteasome system (UPS), as recently
proven for a large number of PAH variants in cellular studies61.
Our results with Pah-R261Q show that selective autophagy may
be involved in the degradation of a PAH variant, as strongly
indicated by the colocalization of markers of autophagy Ser403-
phosphorylated p62 and LC3 with mutant PAH. In the case of the
lightly aggregating Enu1 variant p.V106A-PAH there is no
colocalization of these markers with PAH, and the aggregates
seem to enter the nucleus where they may also be degraded by the
nuclear UPS. There is an intricate cross-talk between the UPS and
autophagy62,63, and it is thus likely that PAH amyloid-like
aggregates in Pah-R261Q that are not effectively processed by the
UPS can be co-aggregated with phosphorylated p62 for autop-
hagic processing51,64.
Although insoluble deposits may protect from oxidative stress65,
amyloid-like aggregation-prone conformers—e.g., resulting from
mutations—perturb cellular homeostasis and induce oxidative
stress, increasing the production of reactive oxygen species (ROS)
at the cellular and tissue levels53. Toxic aggregation in the cyto-
plasm overwhelms the protein quality control system, resulting in
increased ROS, further exacerbation of protein aggregation53, and
activation of p62/SQTM1 by phosphorylation51. Together, our
results point to an oxidative and cellular stress condition in Pah-
R261Q mice associated with a toxic aggregation of the PAH var-
iant. The reduction of BH4 levels manifested in the liver of Pah-
R261Q has also been observed in other disorders associated with
oxidative stress2. In hepatocytes, BH4 also acts as the cofactor of
alkylglycerol monooxygenase2, an enzyme involved in the degra-
dation of ether lipids. Alteration of BH4 synthesis mainly affects
the entire cellular lipidome66, providing a link between oxidative
stress and alterations of lipid metabolism, the two main comor-
bidities postulated from the metabolic characterization of Pah-
R261Q mice (Table 1). As part of the physiological and metabolic
characterization of Pah-R261Q, we noted three related findings:
slightly increased body weight of males (26.8 ± 0.4 vs. 25.1 ± 0.3 g
(WT)), lower RER in the resting period, and higher serum levels of
some metabolites that have been associated with adiposity and
altered lipid metabolism, namely trimethyllysine, leucine, and
isoleucine31. Although no gender-associated changes were found
for any parameter or metabolite measured in this work for Pah-
R261Q compared to WT, including RER and relevant metabolites,
a priori indicates a similar propensity for altered metabolism in
both genders, only males were heavier than theirWT counterparts.
A male-specific body weight increase due to altered lipid meta-
bolism and adiposity has been detected in other mice and human
studies, which has been associated with a different genetic archi-
tecture and potential sex chromosome effects on metabolism
(reviewed in ref. 67).
A recent study has also reported the reduction of soluble BH4
in the liver lysates of Enu1 and Enu1/2 mice and the decrease has
been linked to the entrapment of the cofactor in aggregates of the
p.V106A-PAH variant45, resulting in a secondary BH4-deficiency.
Here, we measured total BH4 in non-centrifuged homogenates,
showing a net reduction in Pah-R261Q mice, which is also sup-
ported by the upregulation of Gchfr-mRNA (Table 2). Further-
more, no decrease of hepatic BH4 was measured by the same
method in liver Enu1/2mice43, supporting that the BH4 reduction
in Pah-R261Q is PAH mutation-specific and associated with the
formation of large amyloid-like aggregates and oxidative stress.
Oxidative stress in Pah-R261Q mice elicits the activation of the
antioxidant response, as seen by increased serum levels of β-
hydroxybutyrate33, as well as an increase in total antioxidant
capacity measured by the Trolox assay. Likewise, the reduction of
quinolinic acid could also be linked to an increased synthesis of
NAD+, which polymerizes to poly ADP-ribose for the protection
of DNA in case of oxidative stress36,37. Conversely, increased β-
oxidation (demonstrated by lower RER and elevated β-hydro-
xybutyrate) and the concomitant increase in anaplerosis, sup-
ported by the observed reduction in α-ketoglutaric acid and other
anaplerotic amino acids and metabolites (Table 1) has also been
shown to cause an increase in oxidative stress and
inflammation38. Another sign of oxidative stress in Pah-R261Q is
the upregulation of Dnajc12, the specific co-chaperone of the
aromatic amino acid hydroxylases, which was not altered in
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Enu142. Interestingly, overexpression of Dnajc12 has been asso-
ciated with oxidative stress68,69. On the other hand, the down-
regulation of both the transcription factor Hsf1 and the
chaperone Hsp70 appears somehow counterintuitive in this
context since Hsf1 in mammals is the primary regulator of the
heat shock response, which is activated by cellular stress and
elicits transcriptional upregulation of major HSPs, notably
Hsp7070. In contrast, downregulation of Hsf1 and consequent
reduction in expression of HSF1 target genes is observed in
neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and
Huntington’s diseases, characterized by toxic amyloid deposits71,
and a similar downregulation of Hsf1 and Hsp70 is also observed
in this case.
In conclusion, the observation of amyloid-like PAH aggregates
in the liver of the Pah-R261Q mouse introduces the concept of
toxic gain-of-function for specific PKU-associated mutations.
Overall, our results suggest that the lipid profile alterations and
oxidative stress found in these mice are linked to intracellular
toxic aggregation of the p.R261Q-PAH variant rather than to
the severity of the HPA and/or the diet. The Pah-R261Q mouse
model thus represents a unique research tool to support the
evaluation and discovery of additional biomarkers in PKU and to
investigate mutation-specific comorbidities, of benefit to the large
number of PKU patients harboring the R261Q mutation. Inter-
estingly, recent studies aiming to assess the prevalence of
comorbid associations among large groups of adult PKU patients
are starting to reveal several conditions in addition to the known
neuropsychiatric disorders, including overweight and renal and
cardiovascular dysfunctions5,6,72. A proper patient stratification
that takes into account the predisposition of the coded PAH
variants to amyloid-like aggregation is expected to result in a
better association of the comorbidities and improved patient-
tailored treatment, encouraging follow-up investigations of the
PAH aggregates. Lastly, this mouse model might contribute to
investigations on pharmacological chaperone-based therapies
targeting unstable PAH variants.
Methods
Materials. All chemicals in this section were acquired from Sigma-Aldrich unless
otherwise indicated. Animals evenly matched for sex were distributed in each
group for the different experiments presented. Recombinant human WT-PAH and
p.R261Q-PAH proteins were expressed and purified using the pMAL expression
vectors18,19 coding for the fusion protein maltose-binding protein (MBP)-(pep)xa-
PAH), where (pep)xa is the cleavage site for the restriction protease Factor Xa. The
fusion proteins were expressed in Escherichia coli TB1 cells at 28 °C for 16–18 h
with 1 mM IPTG and purified by affinity chromatography with amylose resin
(New England Biolabs) with elution with 10 mM maltose. The fusion proteins were
cleaved for 3 h with Factor Xa (New England Biolabs) at a protease:PAH ratio of
1:300. The tetrameric purified WT-PAH and p.R261Q-PAH proteins were isolated
by size exclusion chromatography on a Superdex HiLoad 16/600 200 column
(GE Healthcare) in 20 mM Hepes pH 7, 200 mM NaCl.
Generation of Pah-R261Q knock-in mouse. The constitutive knock-in mouse
model was generated by Taconic Biosciences GmbH (Köln, Germany) via CRISPR/
Cas9-mediated gene editing. The guide RNA target sequence+ protospacer adja-
cent motif (PAM) sequence 5′-AGTGGAAG_ACTCGGAAGGCC_AGG-3′ (non-
seed sequence_seed sequence_PAM) was designed and guide RNA was prepared as
a hybrid of CRISPR-RNA (crRNA; 6 ng/µl) (Dharmacon, Lafayette, USA) and
trans-activating crRNA (tracrRNA; 10.5 ng/µl) (Dharmacon, Lafayette, USA). The
guide RNA was co-injected into C57BL/6N zygotes - essentially as described20—
along with Cas9 protein (55 ng/µl; New England Biolabs, Ipswich, USA) and
homology-directed repair (HDR) oligonucleotide (5′-GCTTAGATCCATGCCTAA
TGTACTGTGTGCAGTGGAAGACTTGGAATGCCAGGCCACCCAAGAAATC
TCGAGACGACAGTAAGCCAG-3′) (100 ng/µl), from Integrated DNA Technol-
ogies, Coralville, USA. This HDR oligonucleotide harbored the point mutation
c.782 G > A (p.Arg261Gln) to be introduced in exon 7 of the Pah gene on murine
chromosome 10 (point mutation and exon annotation according to NCBI tran-
script NM_008777.3) as well as a silent mutation (c.777C > A) to create an addi-
tional restriction site (BsmI) for analytical purposes (Supplementary Fig. 2). These
CRISPR reagents were microinjected (until the pronucleus swells up, typically ~1
pl) into 304 mouse embryos resulting in a total of 51 pups born, and three animals
(5.9%) displayed positive detection of the R261Q knock-in allele.
Confirmation of the on-target mutation was completed as detailed73,74 whereas
verification of the absence of undesired potential off-target modifications was
achieved by heteroduplex mobility assays conducted on the top 16 hits originated
from BLAST analysis of the guide RNA onto M. musculus genome assembly
(GRCm38/mm10) (Supplementary Table 1).
Animal husbandry and colony expansion. The animal studies were approved by
the Norwegian Food Safety Authority and performed at the Laboratory Animal
Facility, University of Bergen, according to the guidelines and standards from the
Regulation on the use of animals in the research of this institution. Mice were
housed in a temperature-controlled (21 °C and 50% air humidity) environment
with 12 h light/dark cycles. Food (standard chow pellets) and water were available
ad libitum.
The colony was continuously backcrossed to avoid genomic drift. Every
6 months wild-type mice (C57BL/6J, males and females every second time) were
bought from an approved vendor (Charles River) and bred with heterozygous
PahR261Q/WT mice. Six to eight weeks old heterozygous PahR261Q/WT siblings from
this backcrossing and breeding were used to produce homozygous PahR261Q/R261Q
mice. The resultant PahR261Q/WT and PahWT/WT mice (siblings) from the breeding
were utilized as control counterparts. This method of breeding is recommended to
maintain the strain genetic integrity. We make sure to avoid going beyond three
generations of inbreeding (F3) before we reset the generation by using new
breeding animals from the backcrossing. The strain has been backcrossed eight
times (N8) and the latest mice that have been used in the experiments presented in
this work are from generation N8F3.
Genotyping. In order to determine the mouse genotype, ear biopsies were collected
and DNA was extracted and purified from these tissue samples using the DNeasy
Blood and Tissue kit (QIAGEN) following the manufacturer’s instructions. After
that, DNA was amplified by standard PCR (See primers in Table S4), initial
denaturation at 95 °C/5 min followed by 35 cycles of denaturation-annealing-
extension, 95 °C/30 s, 60 °C/30 s and 72 °C/1 min, with a final extension at 72 °C for
10 min) using Taq Polymerase (New England BioLabs). The PCR product was then
incubated with the endonuclease BsmI (New England BioLabs) for 15 min at 65 °C.
Finally, the digestion fragments were resolved in 2.5% agarose gel electrophoresis
(1× TAE buffer/90 min/90 v) and bands visualized in a ChemiDoc XRS (Bio-Rad
Laboratories) imaging system.
Metabolic cage. The physiological parameters: rate of O2 and CO2 consumption,
food intake and activity of Pah-R261Q and control WT mice (4–5-month old; n=
3–5 mice per group, 121 observations/animal) were directly determined using the
Oxymax-Comprehensive lab animal system (CLAMS, Columbus Instruments),
with data being recorded for 36 h after an acclimatization period of 12 h. Other
valuable calorimetric properties such as respiratory exchange rate (RER) and
energy expenditure were indirectly calculated using Lusk classical equations pro-
vided in the Oxymax processing software.
Rotarod performance test. The assessment of motor function was conducted on a
rotarod instrument (Harvard Apparatus) consisting of a 5 cm plastic grooved rod
and a platform situated approximately 25 cm below equipped with a lever to trigger
the recording for the time of fall. Pah-R261Q and control WT mice (3 months old;
n= 10–11 mice per group) were, initially, habituated to the setting and trained to
stay on the rod for 1 min at a constant speed of 5 rpm. Trained mice were then
placed again on the rod with a gradual acceleration from an initial 4 rpm to a final
40 rpm speed over a 5 min testing period. The latency of fall as well as rod revo-
lutions at fall was logged, and trials were repeated three times, separated by a
15 min break.
L-Phe challenge and BH4-responsiveness. Adult mice (3–4-month-old) were
employed in all the animal experiments of this section. For the effect of L-Phe
challenge, intraperitoneal injection of an L-Phe solution (200 µg/g body weight) to
PahR261Q/R261Q, PahR261Q/WT, and PahWT/WT mice (n= 23, 6 and 4 mice per
group, respectively) was followed by whole blood sampling from the saphenous
vein at time points: 1 day before injection (baseline level) and 35, 85, 150, and
300 min after injection. For BH4-responsiveness, a treatment solution of BH4
(Schircks Laboratories) (12.73 mM BH4, 2% ascorbic acid, and 10% DMSO; in a
dosage of 20 mg BH4/kg body weight) or placebo solution (2% ascorbic acid and
10% DMSO), were injected into Pah-R261Q mice (n= 5–6 mice per group, per
experiment) intraperitoneally twice a day41 for 4 days, before conducting the L-Phe
challenge protocol as indicated above. The obtained blood samples were collected
onto filter paper cards (PerkinElmer) according to the vendor’s guidelines wherein
L-Phe was measured by tandem mass spectrometry in, at minimum, 3 h
fasted mice.
Metabolic markers analysis. In order to obtain serum specimens, whole blood
was collected by cardiac puncture and 1 mL was transferred to a microcentrifuge
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tube. Subsequently, blood samples were left for 45 min at room temperature to
facilitate coagulation, preceding two consecutive centrifugation steps (2.100 rcf,
10 min, and 4 °C) where the respective supernatants were pipetted out to a clean
tube. The isolated serum fractions were stored at −80 °C until examination. The
extracted serum samples from Pah-R261Q and WT mice (4–5 months old; n= 19
mice per group) were subjected to an exhaustive analysis to determine the con-
centration of 72 relevant metabolic biomarkers. Analyses were performed at Bevital
(http://bevital.no/) across four different platforms supporting high-throughput
multi-analyte assays. A combination of chromatographic techniques with mass
spectrometry detection (GC–MS/MS and LC–MS/MS) was applied (See references
for individual experimental protocols in Supplementary Table 2).
Preparation of liver and brain lysates. Mice (age and numbers indicated in the
specific studies) were sacrificed in a carbon dioxide euthanize chamber. Immedi-
ately after, the brain and liver were surgically excised and snap-frozen in liquid
nitrogen, and tissue was manually ground into a fine powder and stored in aliquots
at −80 °C. Liver homogenates from the ground aliquots (~200 mg powder) were
prepared by adding 800 µL of a lysis buffer solution containing 1× PBS and pro-
tease inhibitor cocktail (Roche), a 5 mm diameter stainless steel bead (Qiagen), and
a mechanical disruption step in a Tissue Lyser II (Qiagen) instrument (2× 1 min
30 s, 20 Hz). Cellular debris was then removed through centrifugation (20.000 rcf,
20 min) to obtain a clear supernatant. The total protein concentration of the liver
lysates was determined in a Direct Detect infrared spectrometer (Millipore). For
the Trolox equivalent antioxidant capacity assay, 600 µL of identical lysis buffer, a
mechanical homogenization with a pellet pestle sitting on ice, and a modified
centrifugation step (18.000 rcf, 10 min) was preferred.
Brain extracts were prepared by powder homogenization in 10× volume of
50 mM Tris-HCl, pH 7.5, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 1 μM leupeptin,
1 μM pepstatin, and 200 μM PMSF, at otherwise identical experimental conditions
as standard liver extracts (see above).
Neurotransmitters, BH4, and amino acid determination in tissues. The relative
levels of BH4 in liver and brain and of monoamine neurotransmitter metabolites in
the brain of Pah-R261Q and WT (n= 5–6 mice per group) were measured in liver
and brain lysates of 3–4-month-old mice as reported58. Briefly, tissue lysates were
oxidized for 60 min in the dark by 0.5 g/L iodine and 0.1 g/L potassium iodide in
0.1 M HCl. The oxidation was stopped by adding 2 g/L ascorbic acid and adjusting
the pH to 8.5 with NaOH before incubation with calf intestine alkaline phosphatase
(Roche Applied Science) at 37 °C for 1 h. The lysates were then adjusted to pH
2 with HCl and deproteinized (Ultrafree-MC filters, Millipore) before BH4 and
neurotransmitters were measured by HPLC75.
The relative levels of the amino acids L-Phe, L-Tyr, and L-Trp of Pah-R261Q
and WT (n= 5–6 mice per group) were measured in liver and brain lysates of 3–4-
month-old mice as reported76. Samples were prepared according to the
Phenomenex EZ:faast™ kit’s manual, with the following modifications: prior to
amino acid extraction and derivatization, 20 μL of each internal standard solution
containing 100 μmol/L Phe-d5 and 20 μmol/L Tyr-d4 (in 50 mmol/L HCl) were
added to 20 μL of sample lysate. Using the kit’s reagents, the amino acids were
derivatized with propyl chloroformate resulting in the addition of propyl formate at
the amine moiety and a propyl group at the carboxylic end of the amino acids,
respectively. The hydroxy group of Tyr was also derivatized by the addition of a
propyl formate group, and the amino acids were then measured by
LC–ESI–MSMS76.
PAH enzymatic activity assay. Liver lysates were first loaded into 0.5 mL Zeba-
Spin desalting columns (7.000 Da cutoff; ThermoFisher Scientific), previously
equilibrated with 20 mM HEPES, pH 7.0, 200 mM NaCl, and protease inhibitor
cocktail solution, and centrifuged (1.700 rcf) for 2 min. PAH activity in the
homogenates was measured at 25 °C using 5–20 µg of total protein in each assay,
with 1 mM L‐Phe in 20 mM Na–Hepes, 0.2 M NaCl, pH 7.0, containing catalase
(0.04 mg/ml). After 4 min preincubation at 25 °C, ferrous ammonium sulfate
(100 µM) was added, and the reaction triggered after 1 min by adding 200 µM BH4
and 5mM DTT (final concentrations in the assay). The reactions were allowed to
run for 2 min and stopped with 2% acetic acid in ethanol. Under these conditions,
PAH activity was linear to the amount of protein in the extracts. L‐Tyr formed was
quantified by HPLC with fluorimetric detection.
Immunoblotting. Protein immunodetection was performed by Western blot. Total
protein (2.5 µg/well) was separated using 10% polyacrylamide gel and immuno-
detected by using primary antibodies, 1:5000 for primary antibody α-PAH (1:5000;
Millipore-MAB5278), α-ubiquitin (1:500; Thermo Fisher Scientific-131600);
α-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1000; Abcam-ab9485),
and 1:2500 for secondary antibodies goat anti-mouse (GAM) (Bio-Rad Labora-
tories) and goat anti-rabbit (GAR) (Bio-Rad Laboratories), conjugated to horse-
radish peroxidase. Quantification of non-ubiquitinated and mono-
ubiquitinated PAH and GAPDH proteins was performed by gel band
densitometry.
Immunofluorescence and IHC. Mice (4–5-month-old) were anesthetized with
pentobarbital (20 mg/kg, IP), and transcardially perfused with 50 ml of warm saline
(0.9%, 37 °C), followed by 50 ml of warm paraformaldehyde (4%, 37 °C) in 0.16M
phosphate buffer (PBS; pH 7.2). The hepatic tissue was dissected out and postfixed
in the same fixative for 3 h at 4 °C and subsequently stored in 20% sucrose diluted
with PBS containing 0.01% sodium azide (Sigma) and 0.02% Bacitracin (Sigma) at
4 °C overnight. Tissues were embedded with Optimal cutting temperature (OCT)
compound (Tissue Tek, Miles Laboratories, Elkhart, Ind., USA), frozen and cut in a
cryostat (Microm, Heidelberg, Germany) at 20 or 50 μm thickness, collected and
stored free-floating in PBS at 4 °C or mounted onto SuperFrost Plus microscope
slides (ThermoFisher Scientific), dried at room temperature for 30 min and stored
at −80 °C until use.
For immunofluorescence, Triton-X 100 (0.5%) was used to permeabilize the
tissues followed by blocking with 5% FBS in PBS for 1 h prior to the primary
antibody incubation. Tissues were then incubated overnight at 4 °C in a humidity
chamber with the correponding primary antibody, α-PAH (1:100; Abcam-
ab178430), α-Ubiquitin N-terminal (1:200; ABIN350072), anti-NUP98 (1:100;
Abcam-ab50610), α-phospho-p62 (S403) (1:200; MBL-D343-3), and goat anti-
LC3B (1:100; Signalway antibody-C48312), in 10% (w/v) NGS, 1× PBS, pH
7.4 solution. Then, a 30 min incubation in a humidity chamber at 37 °C was carried
out with the corresponding secondary antibody, donkey anti-rabbit IgG H&L
(1:200; Alexafluor 488, Invitrogen-A21206), donkey anti-goat IgG H&L (1:400;
Alexafluor 555, Abcam-ab150130), donkey anti-goat IgG (1:200; Cy3 conjugate,
Millipore-AP180C), goat anti-rat IgG H&L (1:100; TRITC, Jackson
immunoresearch-112-025-143), goat anti-rabbit IgG H&L (1:200; Alexafluor 647,
Invitrogen-A21245), donkey anti-rat IgG H&L (1:200; Alexafluor 488,
ThermoFisher Scientific-A21208), in the same blocking solution. A washing step of
15 min with 1× PBS, pH 7.4 was included prior to and after each incubation period.
Hoechst or DAPI, as indicated, were used to counterstain the nucleus for 30 min at
RT followed by washing in PBS and mounted with DABCO mounting media.
Images were acquired by using Leica TCS SP5 confocal microscope (Leica
Microsystem GmbH) using a pinhole airy 1 and a 63×, 1.4 numeric aperture oil
immersion objective. Acquired images were processed using the LAS AF Lite
software (Leica Microsystem). For each sample, a stack of images (n= 14) with a
step-size of either 290 or 170 nm was taken. Fluorescence intensity measurements
were performed using Fiji freeware using the stacks of confocal images. Integrated
density values of each stack were used to compare the relative fluorescence
intensity of the samples. 3D rendering of the confocal images (z-stacks) was
performed by using image analysis software Imaris (Bitplane Inc.). The nuclei
marked with Nup98 (red) and PAH (green) were reconstructed by using the
surface tool.
For immunohistochemistry (IHC), the stored free-floating sections were
employed. Sections were first rinsed in 0.3% H2O2 in PBS for 10 min at RT for
quenching endogenous peroxidase activity, and then incubated with blocking
buffer containing Blocking Serum (VECTOR Laboratories), 0.5% Triton X-100
(Sigma), and 5% bovine serum albumin (Sigma-Aldrich) in PBS for 1 h at RT.
Sections were incubated for 45 min with primary antibody α-PAH (1:800, Abcam-
ab191415) and 30 min with goat anti-rabbit IgG H+ L (1:200, HRP, BioRad-
1706515) secondary antibody, and followed by a 30-min incubation with prepared
VECTASTAIN Elite ABC (VECTOR Laboratories). The sections were immersed in
a peroxidase substrate solution (DAB, Sigma) for 7–8 min and washed with water,
mounted on Super Frost slides, and coverslipped with glycerol/PBS (9:1)
containing 0.1% para-phenylenediamine. Finally, the sections were analyzed and
images were captured using a Leica microscope equipped with a Leica camera. The
average size and size distribution of PAH-positive “particles” in the cytoplasm of
hepatic cells was quantified using ImageJ software. As the PAH staining pattern in
the light microscope (objective 100×) was evenly distributed in WT mouse liver,
the quantification was performed on liver sections of Pah-R261Q and Enu1. Ten
liver sections (30 µm thickness) were randomly selected from each animal. PAH-
positive particles were analyzed in randomly selected regions of the sections. Only
single PAH-positive particles were analyzed and at least 400 particles from each
group, from at least 10–12 hepatic cells, were counted.
Amyloid-like aggregation assay (Amytracker). Amyloid detection was carried
out by recording the fluorescence emission of amyloid ligand heptamer formyl
thiophene acetic acid (Amytracker™ 680; Ebba Biotech) at 680 nm in a 96-well
plate, black F-bottom (Griener Bio-one), for 24 h at 37 °C in a multimode
microplate reader (Tecan spark), with excitation at 540 nm. The time course of the
fluorescence intensity for purified WT-PAH and p.R261Q-PAH (20 µM subunit)
with Amytracker™ 680 (1:1000) was acquired in 20 mM HEPES, 150 mM NaCl, pH
6.0. Samples lacking protein were used as controls and normalized. Three mea-
surements were carried out for each protein.
Transmission electron microscopy (TEM). For TEM of hepatic tissue, 5-month-
old mice (WT and Pah-R261Q) were anesthetized with isoflurane and transcar-
dially perfused with 50 ml of warm saline (0.9%, 37 °C), followed by 50 ml of 2.5%
glutaraldehyde (diluted in a 0,1 M sodium cacodylate buffer) at RT. The hepatic
tissue was dissected out and postfixed in the same fixative for 24 h at 4 °C. The
tissues were then transferred to 0.1 M sodium cacodylate buffer and kept at 4 °C.
Postfixation was performed for 1 h (on ice) in 1% osmium tetroxide (EMS # 19134)
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diluted in 0.1 M sodium cacodylate buffer, followed by two washing steps. The
samples were then dehydrated using a graded ethanol series (30%, 50%, 70%, 96%,
and 3 × 100%) before transferred to a 1:1 solution of 100% ethanol:propylene oxide
(15 min). Samples were then transferred to 100% propylene oxide (15 min) before
gradually introducing agar 100 resin (AgarScientific R1031) drop by drop over the
next hours. Samples were then transferred to a small drop of 100% resin and excess
propylene oxide was allowed to evaporate (1 h). Samples were then transferred to
100% resin and placed in molds and left at RT overnight. The molds were then
placed at 60 °C for 48 h to polymerize. Ultrasections of approximately 60 nm were
placed on 100 mesh Copper grids (EMS #G100H-Cu) and stained with 2% uranyl
acetate (EMS # 22400) and lead citrate (VWR #1.07398). Grids were imaged using
a Jeol JEM-1230 transmission electron microscope at 80 kV. Different organelles
were counted in images acquired at 20.000× magnification from the cytoplasm in
hepatocytes, in liver samples of both WT and Pah-R261Q mice (40 TEM micro-
graphs for each mouse).
For protein TEM with negative staining, 5 µl samples of protein solutions
(20 µg/ml) in the indicated buffer were allowed to be absorbed (1 min) on a glow
discharged, 300 mesh (EMS # G300H-Cu), carbon-coated grid. The grids were then
stained for 1 min in 2% uranyl acetate. Grids were allowed to dry for 30 min before
imaging. The incorporation of two consecutive washing steps with double distilled
water after absorption of the protein improved the background, but we observed
loss of aggregates.
Oxidative stress assay (Trolox). The antioxidant capacity of small molecules
(such as ascorbate, glutathione, and vitamin E) in Pah-R261Q and WT liver
homogenates was determined by the Trolox equivalent antioxidant capacity assay
using the colorimetric Total Antioxidant Capacity Assay kit (Abcam). Samples
were diluted 1:1 with the included reagent Protein Mask to avoid the potential
contribution of other biological species. Otherwise, the standard protocol indicated
in the product manual was followed. Results were obtained by interpolation to a
Trolox (reference antioxidant) standard curve and expressed as Trolox equivalent
antioxidant capacity.
Gene (mRNA) expression. Total RNA was extracted from powdered livers of
Pah-R261Q and WT mice (3-months-old; n= 5–6 per group) with the QIAmp
RNA Blood Mini Kit (QIAGEN) and translated into cDNA using the Reverse
Transcription System (Promega). Quantitative PCR was performed in standard
triplicate assays for each mouse sample with 50 ng of cDNA using TaqMan
technology, an ABI Prism 7700 sequence detector, and the TaqMan Universal PCR
Master Mix from ABI. Detailed information about the specific transcript detection
cannot be given, as we used ABI TaqMan Gene Expression Assays, which are under
a proprietary license, and the exact primer and probe sequence are not disclosed.
The ABI assay numbers for the indicated murine mRNA and NCBI nucleotide
sequence numbers are summarized in Supplementary Table 4. Murine Gapdh-
mRNA was included as a control for normalization and the analyses of the relative
gene expression were performed based on the 2−ΔΔCt method77.
Software. The computer algorithm TANGO47 was used for the prediction of
aggregating regions in the relevant mutants and WT PAH sequences. Calculations
were performed online (http://tango.crg.es/) with default parameters. PAH parti-
cles were analyzed and measured using Fiji ImageJ.
Statistics and reproducibility. Quantitative data are presented as mean ± standard
deviation (SD). Individual values are plotted as circles in both scatter dot plots and
bar graphs, except in the inset of Fig. 1e where the circles represent the mean for
the group for each time point. Statistical significant differences were determined by
unpaired two-tailed t test for pairs of groups, except when indicated, i.e., two-tailed
Mann Whitney U tests were used for the analysis of data in Table 1 and Supple-
mentary Table 2. For comparisons of more than two groups one-way ANOVA
followed by post hoc Tukey test was used, except for data in the inset of Supple-
mentary Fig. 4 where due to unequal variance and sample size Brown–Forsythe and
Welch ANOVA test was used followed by Dunnett’s multiple comparisons test, as
indicated. Note that despite the fact that mean ± SD is presented in this figure, the
analysis is run on mean AUC ± SEM data, which is also the case for the t test
applied on the AUC data in the inset of Fig. 1d and inset of Fig. 2c. We considered
p < 0.05 as statistically significant and p values are provided with accurate numbers
down to <0.0001. Statistical analyses were performed using GraphPad Prism™
(version 8.3.0, San Diego) software and the applied analysis in each case is included
in the corresponding Table and Figure legend only for the results for which sta-
tistical significance was obtained.
For representations of quantitative data, n customarily refers to the number of
independent biological samples (mice) examined in each analysis, except when
explicitly referring to the number of independent enzyme purifications. When
required, i.e., Figure 5c and Supplementary Fig. 7, the number of sections and/or
particles analyzed is also provided in the corresponding figure legend.
The representative Western blots (Fig. 3a, b) have been repeated at least three
times in independent experiments, using different mice in each experiment (n ≥ 3
for each genotype). Densitometric results obtained with the Western blots are
represented in Fig. 3c. The agarose gel in Supplementary Fig. 2c represents the
procedure used for genotyping after breeding and similar results have been
obtained at least 20 times in independent experiments including in total n ≥ 40
mice of each genotype. Representative micrographs showing results from
immunofluorescence and IHC (Figs. 4, 5a,b and 6a,b) have been successfully
repeated with n ≥ 3 for each genotype in independent experiments. The results in
the representative micrograph from TEM with purified p.R261Q-PAH
(Supplementary Fig. 6b) have been observed with n= 3 protein preparations. For
the TEM of hepatic tissue, representative micrographs with the relevant organelles
are shown and have been observed in liver samples from n= 3 mice in each
genotypic group.
Ethical compliance. We have complied with all relevant ethical regulations for
mice breeding, testing and research. The animal experiments in this study have
received the appropriate approval from the Norwegian Food Safety Authority
(Brumunddal, Norway) (approved application 20168698) and performed at the
Laboratory Animal Facility, University of Bergen, according to the guidelines and
standards from the Regulation on the use of animals in the research of this
institution.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data underlying Figs. 1–6, Supplementary Figs. 2c and 3–6, Tables 1 and 2 and
Supplementary Tables 2 and 3 are provided with this paper as a Source Data file. The rest
of the data that support Supplementary Figs. 7 and 8 within this paper, other findings
and the mouse and derived materials will be made available upon reasonable request to











NM_001243043.1, Gapdh-mRNA NM_008084.3 https://www.ncbi.nlm.nih.gov/nuccore/
NM_008084.3 Web-link for PAH structure in complex with BH4 PDB 6HYC (https://
www.rcsb.org/structure/6HYC) Web-link for data on C57BL/6J mouse strain (https://
www.jax.org/strain/000664). Source data are provided with this paper.
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